Effect of distance to health facility on the maintenance of INR therapeutic ranges in rheumatic heart disease patients from Cape Town: No evidence for an association

BMC Health Services Research

Volumn 15, Issue 1, 2015, Pages

  Barth, Dylan D ^a   Zühlke, Liesl J ^a,b   Joachim, Alexia ^a   Hoegger, Tyler ^c   Mayosi, Bongani M ^a   Engel, Mark E ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c Skiza Consulting Ltd   (South Africa)

Author keywords

Distance decay; GIS; INR; RHD

Indexed keywords

ANTICOAGULANT AGENT; WARFARIN;

ADOLESCENT; ADULT; AGED; FEMALE; GEOGRAPHIC INFORMATION SYSTEM; HEALTH CARE DELIVERY; HEALTH CARE FACILITY; HUMAN; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; REGISTER; RHEUMATIC HEART DISEASE; SOUTH AFRICA; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTICOAGULANTS; FEMALE; GEOGRAPHIC INFORMATION SYSTEMS; HEALTH FACILITIES; HEALTH SERVICES ACCESSIBILITY; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; REGISTRIES; RHEUMATIC HEART DISEASE; SOUTH AFRICA; WARFARIN; YOUNG ADULT;

EID: 85018129841     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/s12913-015-0890-4     Document Type: Article

References (23)

1. Wu J-R, Moser DK, Lennie TA, Burkhart PV. Medication adherence in patients who have heart failure: a review of the literature. Nurs Clin North Am. 2008;43:133-153.
2. Gabrysch S, Campbell OMR. Still too far to walk: literature review of the determinants of delivery service use. BMC Pregnancy Childbirth. 2009;9:34.
3. Freehauf C, Van Hove JLK, Gao D, Bernstein L, Thomas JA. Impact of geographic access to care on compliance and metabolic control in phenylketonuria. Mol Genet Metab. 2013;108:13-17.
4. McLaren ZM, Ardington C, Leibbrandt M. Distance decay and persistent health care disparities in South Africa. BMC Health Serv Res. 2014;14:541.
5. Tanser F, Gijsbertsen B, Herbst K. Modelling and understanding primary health care accessibility and utilization in rural South Africa: An exploration using a geographical information system. Soc Sci Med. 2006;63:691-705.
6. Målqvist M, Sohel N, Do TT, Eriksson L, Persson L-Å. Distance decay in delivery care utilisation associated with neonatal mortality. A case referent study in northern Vietnam. BMC Public Health. 2010;10:762.
7. Feikin DR, Nguyen LM, Adazu K, Ombok M, Audi A, Slutsker L, et al. The impact of distance of residence from a peripheral health facility on pediatric health utilisation in rural western Kenya. Trop Med Int Heal. 2009;14:54-61.
8. Bonow RO, Carabello BA, Chatterjee K, de Leon AC, Faxon DP, Freed MD, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. J Am Coll Cardiol. 2006;48:e1-e148.
9. Marijon E, Mirabel M, Celermajer DS, Jouven X. Rheumatic heart disease. Lancet. 2012;379:953-64.
10. Singer DE, Albers GW, Dalen JE, Go AS LJ, Manning WJ. Antithrombotic therapy in atrial fibrillation: the seventh ACCP conference on antithrombotic and thrombolytic therapy antithrombotic therapy in atrial fibrillation the seventh ACCP conference on antithrombotic and thrombolytic. Therapy. 2006;126:429S-56S.
11. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983-988.
12. Hirsh J, Dalen JE, Anderson DR, Poller L, Bussey H, Ansell J, Deykin D. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 2001;119:8S-21S.
13. Lefkowitz JB. Coagulation pathway and physiology. In: Kottke-Marchant K, editor. An algorithmic approach to hemostasis testing. Northfield, IL: College of American Pathologists; 2008.
14. Mant J, Hobbs FDR, Fletcher K, Roalfe A, Fitzmaurice D, Lip GYH, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007;370:493-503.
15. Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010;376:975-83.
16. Hirsh J, Fuster V, Ansell J, Halperin JL. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation. 2003;107:1692-711.
17. Go AS, Hylek EM, Chang Y, Phillips KA, Henault LE, Capra AM, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation. JAMA. 2013;290:2685-2692.
18. Karthikeyan G, Zühlke L, Engel M, Rangarajan S, Yusuf S, Teo K, et al. Rationale and design of a Global Rheumatic Heart Disease Registry: The REMEDY study. Am Heart J. 2012;163:536-540.
19. Schmitt L, Speckman J, Ansell J. Quality assessment of anticoagulation dose management: comparative evaluation of measures of time-in-therapeutic range. J Thromb Thrombolysis. 2003;15:213-2016.
20. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69:236-9.
21. Evans J. GIS mapping software. Health Manag Technol. 1997;18:58-60.
22. Birk HO, Gut R, Henriksen LO. Patients' experience of choosing an outpatient clinic in one county in Denmark: results of a patient survey. BMC Health Serv Res. 2011;11:262.
23. Eaddy MT, Cook CL, Day KO, Burch SP, Cantrell CR. How patient cost-sharing trends affect a literature review. P&T. 2012;37:45-55.